John Mulcahy
Phoenix, AZNPI 1255327193
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $672,723 of the $840,588 with a category attached, or 80.0%. Boston Scientific accounts for 90.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $230,538 and has fallen 72.1% since, to $64,213 in 2025.
Across 743 payments — averaging $1131.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$757K
- Coloplast$84K
- Antares Pharma, Inc.$50
What the payments were for
- Consulting fees$14,9262%
- Speaking & faculty fees$672,72380%
- Travel & lodging$81,88310%
- Food & beverage$22,4323%
- Education$48,6246%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 646 | $756,911 |
| Coloplast | 96 | $83,627 |
| Antares Pharma, Inc. | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS 700 CXR RTE KIT$329,343
- CROSSBOSS$166,271
- TACTRA$91,027
- TITAN$82,822
- AMS$76,024
- AMS AMBICOR$35,718
- GENERAL MALE SUI$16,149
- GENERAL - THERAPIES$8,362
- AdVance XP$8,253
- ADVANCE$4,357
- GENERAL PAIN MANAGEMENT$2,538
- GENERAL ERECTILE DYSFUNCTION$1,781
- AMS 700$775
- Spectra$147
- RESTORELLE$126
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.